Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanoma Meeting Abstract
| Authors: | Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R. J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; Sacco, J. J.; Shoushtari, A. N.; Orloff, M.; Carvajal, R. D.; Hamid, O.; Abdullah, S. E.; Holland, C.; Goodall, H.; Nathan, P.; Piperno-Neumann, S. |
| Abstract Title: | Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanoma |
| Meeting Title: | Immunotherapy Bridge 2021 and Melanoma Bridge 2021 |
| Journal Title: | Journal of Translational Medicine |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 1-4 |
| Meeting Location: | Virtual |
| ISSN: | 1479-5876 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-04-05 |
| Start Page: | 142 |
| Language: | English |
| ACCESSION: | WOS:000777987200008 |
| PROVIDER: | Clarivate Analytics Web of Science |
| PROVIDER: | wos |
| PMCID: | PMC8981597 |
| PUBMED: | 35379244 |
| DOI: | 10.1186/s12967-022-03290-1 |
| Notes: | Meeting Abstract: 7 -- Source: Wos |
